Interim positron emission tomography scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

Blood

Volumn 115, Issue 4, 2010, Pages 775-777

  Horning, Sandra J ^a   Juweid, Malik E ^b   Schöder, Heiko ^c   Wiseman, Gregory ^d   McMillan, Alex ^e   Swinnen, Lode J ^f   Advani, Ranjana ^a   Gascoyne, Randy ^g   Quon, Andrew ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

^e STANFORD UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCORTICOGRAPHY; HUMAN; KAPPA STATISTICS; LARGE CELL LYMPHOMA; MEDICAL INFORMATION SYSTEM; MULTIPLE CYCLE TREATMENT; NUCLEAR MEDICINE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REPRODUCIBILITY; UNITED KINGDOM; MEDICAL EDUCATION; OBSERVER VARIATION; SCINTISCANNING; STANDARD; STATISTICS; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EDUCATION, MEDICAL, CONTINUING; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NUCLEAR MEDICINE; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; REPRODUCIBILITY OF RESULTS; VINCRISTINE;

EID: 77949312595     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-234351     Document Type: Article

References (12)

1. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007;48(suppl 1):19S-27S.
2. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
3. Radford J, O'Doherty M, Barrington S, et al. Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a "negative" FDG-PET scan after 3 cycles ABVD [abstract]. Blood. 2008;112(11):369.
4. Moskowitz C, Hamlin PA, Horwitz SM, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood. 2006;108(11):532.
5. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309-318.
6. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL). Blood. 2008;112(11):371.
7. Haioun C, Itti E, Rahmouni A, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376-1381. (Pubitemid 41129604)
8. Thomas A, Gingrich R, Smith BJ, Jacobus LS, Habermann TM, Link BK. FDG-PET as predictor of outcome in diffuse large B-cell lymphoma (DLBCL): first analysis of "indeterminate" reports. Proc Am Soc Clin Oncol. 2008;26[suppl 15]:8510.
9. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
10. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10):1626-1632. (Pubitemid 47572710)
11. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514-1523. (Pubitemid 41222425)
12. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.